Osiyemi, O., De Wit, S., Ajana, F., Bisshop, F., Portilla, J., Routy, J. P., Wyen, C., Ait-Khaled, M., Leone, P., Pappa, K. A., Wang, R., Wright, J., George, N., Wynne, B., Aboud, M., van Wyk, J., & Smith, K. Y. (2022). efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial . Clinical infectious diseases, 75, 975–986. http://access.bl.uk/ark:/81055/vdc_100167547598.0x000033